XNK Therapeutics AB announced that the company has entered into a research collaboration with the Karolinska University Hospital, Sweden, to evaluate the suitability of the company’s autologous natural killer cell therapy candidate XNK02 as a novel therapy for treatment of acute myeloid leukemia.
